SCP
VRTX icon

Seizert Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Seizert Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,165
Closed -$1.68M – 177
2024
Q4 		$1.68M Sell
4,165
-6,546
-61% -$3.03M 0.08% 111
2024
Q3 		$4.98M Buy
10,711
+20
+0.2% +$9.61K 0.22% 81
2024
Q2 		$5.01M Sell
10,691
-1,466
-12% -$636K 0.25% 71
2024
Q1 		$5.08M Sell
12,157
-415
-3% -$175K 0.23% 72
2023
Q4 		$5.12M Sell
12,572
-4,823
-28% -$1.78M 0.26% 71
2023
Q3 		$6.05M Sell
17,395
-335
-2% -$117K 0.32% 59
2023
Q2 		$6.24M Sell
17,730
-11,069
-38% -$3.73M 0.33% 60
2023
Q1 		$9.07M Sell
28,799
-7,582
-21% -$2.27M 0.5% 52
2022
Q4 		$10.5M Sell
36,381
-3,438
-9% -$1.05M 0.56% 48
2022
Q3 		$11.5M Sell
39,819
-165
-0.4% -$47.5K 0.65% 46
2022
Q2 		$11.3M Sell
39,984
-94
-0.2% -$25.2K 0.6% 46
2022
Q1 		$10.5M Buy
40,078
+1,480
+4% +$351K 0.48% 53
2021
Q4 		$8.48M Buy
38,598
+3,640
+10% +$708K 0.38% 62
2021
Q3 		$6.34M Buy
34,958
+1
+0% +$195 0.29% 64
2021
Q2 		$7.05M Buy
34,957
+1,098
+3% +$230K 0.34% 64
2021
Q1 		$7.28M Buy
+33,859
New +$7.44M 0.38% 65

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Seizert Capital Partners's VRTX Position: Q1 2025 in Review

Seizert Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 4,165 shares — an estimated $1.68M sold.

Seizert Capital Partners first reported a position in VRTX in Q1 2021 and held it in 16 quarters. The position peaked at $11.5M in Q3 2022. 1,617 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Seizert Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Seizert Capital Partners sold 4,165 Vertex Pharmaceuticals shares in Q1 2025, an estimated $1.68M.
  • Seizert Capital Partners first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 16 quarters.
  • Seizert Capital Partners's Vertex Pharmaceuticals position peaked at $11.5M in Q3 2022.
  • 1,617 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Seizert Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.